FORM PTO-1449 (modified)
To: U.S. Department of Commerce
Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket No.	Client Ref.
053529-5007-01	

Applicant: Berkley LYNCH *et al.*

Appln. No.: 10/725,189

Filing Date: December 2, 2003

Examiner: Unassigned | Group Art Unit: 1711

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
CyW	AR	20030009024 A1	01/09/2003	Curtis			
CyW	BR	20020142383 A1	10/03/2002	Merkulov *et al.*			
	CR						

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract Enclosed	English Abstract No	Translation Readily Available Enclosed	Translation Readily Available No
	DR								
	ER								
	FR								

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

CyW	GR	Bajjalieh SM, *et al.* SV2, a brain synaptic vesicle protein homologous to bacterial transporters. Science 1992; 257(5074):1271-1273
	HR	Bajjalieh SM, *et al.* Brain contains two forms of synaptic vesicle protein 2. Proc Natl Acad Sci (USA). 1993; 90(6):2150-2154
	IR	Bajjalieh SM, *et al.* Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci. 1994 ; 14(9):5223-5235
	JR	Buckley, K *et al.* Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells. J Cell Biol. 1985; 100(4):1284-1294
	KR	Crowder, KM *et al.* Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci (USA). 1999; 96(26):15268-15273
	LR	Feany, MB *et al.* The synaptic vesicle protein SV2 is a novel type of transmembrane transporter. Cell. 1992; 70(5):861-867
	MR	Fuks, B, *et al.* Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines. European Journal of Pharmacology 478 (2003) pp. 11-19
	NR	Hayashi, M *et al.* Synaptic vesicle protein SV2B, but not SV2A, is predominantly expressed and associated with microvesicles in rat pinealocytes. Adv Exp Med Biol. 1999; 460:91-93
	OR	Janz, R *et al.* SVOP, an evolutionarily conserved synaptic vesicle protein, suggests novel transport functions of synaptic vesicles. J Neurosci. 1998; 18(22):9269-9281
	PR	Janz, R *et al.* SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release. Neuron. 1999; 24(4):1003-1016
	QR	Janz, R. Knockout mice and SV2 synaptic-vesicle proteins. University of Texas Health Science Center at Houston Neuroscience Research Center Newsletter, 2001; 7(3):1,4-5
CyW	RR	Lynch B, *et al.* The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. PNAS, June 29, 2004, vol. 101, no. 26, pp. 9861-9866

Examiner [signature] | Date Considered: 2/8/06

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

USPTO SEP 23 2004 PATENT & TRADEMARK OFFICE

Attorney Docket No.	Client Ref.
053529-5007-01	

Applicant: Berkley LYNCH *et al.*

Appln. No.: 10/725,189

Filing Date: December 2, 2003

Examiner: Unassigned | Group Art Unit: 1711

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR						
	BR						
	CR						

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract Enclosed	English Abstract No	Translation Readily Available Enclosed	Translation Readily Available No
	DR								
	ER								
	FR								

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

C/W	GR	Margineanu, DG *et al.* Levetiracetam: Mehanisms of action. *In*: Antiepileptic Drugs, 5ht Editiion. Levy,RH *et al. eds.* 2002; Lippincott Williams & Wilkins, Philadelphia, PA. Pp. 419-427
	HR	Noyer, M *et al.* The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol. 1995; 286(2):137-146
	IR	Pyle, RA *et al.* Phosphorylation of synaptic vesicle protein 2 modulates binding to synaptotagmin. J Biol Chem. 2000; 275(22):17195-17200
	JR	Schivell, AE *et al.* Isoform-specific, calcium-regulated interaction of the synaptic vesicle proteins SV2 and synaptotagmin. J Biol Chem. 1996; 271(44):27770-27775
	KR	Son, Y-J *et al.* The synaptic vesicle protein SV2 is complexed with an alpha5-containing laminin on the nerve terminal surface. J Biol Chem. 2000; 275(1):451-460
	LR	Xu, T *et al.* SV2 modulates the size of the readily releasable pool of secretory vesicles. Nat Cell Biol. 2001; 3(8):691-698
	MR	Nagase *et al.*, Prediction of the Coding Sequences of Unidentified Human Genes. XI. The Complete Sequences of 100 New cDNA Clones from Brain Which Code for Large Proteins *in vitro*. DNA Research 5, 1998, 277-286
C/W	NR	Genbank Accession 094841, May 1, 1999, KIAA0736 Human SV2
	OR	

Examiner [signature] Date Considered: 2/8/06

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.